Prostate Cancer Clinical Trial
Official title:
A Case-Control Study of Prostate Cancer in the Greater Baltimore Area: An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males
This study will examine the association of genetic variants and gene expression patterns with
the risk of prostate cancer. There will be (It will include?) genotype analysis of blood DNA
from 600 patients with the disease and from 600 healthy people, and there will be a gene
expression analysis of prostate tumors. Prostate cancer is a leading cause of death among men
in Western countries. It is estimated that 220,000 or more new cases of the disease will
occur in the United States during 2004. The disease incidence is rising. About 25% to 30% of
the cancers become aggressive. The nonhereditary disease rarely occurs in men who are younger
than age 40. There are large differences in incidence by geography and race. The highest
rates are seen among African-American men in the United States. Also, although Caucasians
have a lower rate of disease incidence and mortality in the United States, the rates among
them are high compared with rates in some European countries. The reasons for such
differences are not well understood, but both environmental and genetic risk factors are
thought to be involved.
Patients ages 40 to 80 years who have had prostate cancer confirmed within the past 6 months,
who reside in Baltimore City or adjacent metropolitan counties, and who were born in the
United States may be eligible for this study. They will be recruited in collaboration with
the Departments of Pathology and Urology at the University of Maryland and the Baltimore
Veterans Affairs Medical Center. Those men serving as controls in this study will be
identified through the Department of Motor Vehicles database and will be matched by age and
race with the patients who have cancer. The study will include 600 participants with prostate
cancer and 600 participants in the control group.
Trained interviewers will administer two questionnaires. The primary questionnaire will be
used to assess information such as medical and cancer history, tobacco use, current
medications, occupational history, family medical history, and socioeconomic status. A
supplemental questionnaire will pertain to patients' exposure to risk factors for prostate
cancer. It will assess the human body, diet, medical history, family medical history, and
sexual history. The section on sexual history will be self-administered.
Patients will undergo collection of blood and urine for various tests. For cancer patients
with prostate surgery, there will also be a collection of tissue, to be performed at the time
that the prostate gland is scheduled for surgical removal. The pattern of gene expression
will be analyzed in low- and high-stage tumors.
There will be no direct benefit from participating in the study, but participants will
receive an incentive of up to $75 to participate in the study. No form of treatment is
involved in this study. However, it is hoped that the study findings will improve
researchers' understanding of prostate cancer biology with respect to the causes of the
health variances between African-Americans and Caucasians.
...
We are conducting an epidemiological prostate cancer case-control study in Baltimore,
Maryland. Participants will be African American and Caucasian males who reside in Baltimore
city and surrounding areas. The study is ongoing and will recruit 1000 prostate cancer cases
and 1000 population-based controls. The cases are recruited at two Baltimore hospitals, the
Veterans Affairs Medical Center and the University of Maryland Center. Cases will have
pathologically confirmed prostate cancer. The population-based controls are identified
through the Maryland Department of Motor Vehicle Database, and are frequency-matched by age
and race to cases. Enrollment of controls started concurrently with case accrual. The first
12 months of the study constituted a pilot study, during which we evaluated the recruitment
procedures. The study involves the administration of two questionnaires and collection of
blood from all study subjects. The two questionnaires consist of a main questionnaire and a
supplemental questionnaire. The questionnaires evaluate family cancer history, tobacco use,
medication, occupational history, socioeconomic status and risk factors for prostate cancer.
Fresh-frozen tumor specimens will be obtained from cancer patients if available. The study is
supported by an epidemiological infrastructure that has been developed by our resource
contractor at the University of Maryland for a lung cancer case-control study. This lung
cancer study is ongoing, and the controls that are recruited for the prostate cancer study
are joint controls with the lung cancer study. Hence, population-based male controls
recruited by our contractor have double eligibility for the concurrent lung and prostate
cancer studies. To achieve an age and race matching of cases and controls in the prostate
study, we will over-sample male controls in the lung study.
We will test the primary hypothesis that genes and environmental exposures, including
infections and medical history, and interactions between those exposures and genetic factors
modify prostate cancer susceptibility. As the secondary goal, we will study gene expression
profiles of prostate tumors to identify changes in tumor biology that are associated with
exposure to genetic and environmental risk factors. It is a focus of this research to
identify mechanisms in tumor biology that may cause the aggressive nature of prostate cancer
in African American men.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |